Loomis Sayles & Co. L P Acquires 48,120 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Loomis Sayles & Co. L P boosted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 184,623 shares of the biotechnology company's stock after acquiring an additional 48,120 shares during the quarter. Loomis Sayles & Co. L P owned 0.30% of Ascendis Pharma A/S worth $27,566,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the business. Westfield Capital Management Co. LP boosted its position in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after buying an additional 170,942 shares during the last quarter. Valence8 US LP bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $685,000. Massachusetts Financial Services Co. MA increased its position in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock worth $278,760,000 after buying an additional 155,971 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of Ascendis Pharma A/S by 23.2% during the third quarter. Advisors Asset Management Inc. now owns 4,742 shares of the biotechnology company's stock valued at $708,000 after acquiring an additional 894 shares during the period. Finally, Avior Wealth Management LLC grew its position in shares of Ascendis Pharma A/S by 3.0% during the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company's stock worth $1,226,000 after acquiring an additional 240 shares during the last quarter.

Ascendis Pharma A/S Trading Up 2.9 %

NASDAQ ASND traded up $3.75 during trading on Tuesday, hitting $134.60. 353,518 shares of the company traded hands, compared to its average volume of 451,863. The company has a market capitalization of $8.16 billion, a P/E ratio of -16.52 and a beta of 0.66. The business has a fifty day simple moving average of $133.04 and a 200 day simple moving average of $132.17. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Equities research analysts predict that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Analysts Set New Price Targets

ASND has been the subject of several analyst reports. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. Wells Fargo & Company boosted their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Bank of America boosted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Finally, TD Cowen decreased their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.